CARING AMBASSADORS

Empowering People to be Ambassadors of their Own Health Since 1997.

LUNG CANCER PROGRAM


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer
Literature Review, April  2016

 

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Phiboonchaiyanan PP1, Kiratipaiboon C2, Chanvorachote P3. Chem Biol Interact. 2016 Mar 3;250:1-11. doi: 10.1016/j.cbi.2016.03.005. [Epub ahead of print]

Highly stable polyglutamate derivatives/siRNA polyplex efficiently down-relegate survivin expression and augment the efficacy of cisplatin. Wang Z1, Zou H1, Wang Z1, Wu J1, Xia Z2, Feng M3. Int J Pharm. 2016 Mar 31;505(1-2):24-34. doi: 10.1016/j.ijpharm.2016.03.062. [Epub ahead of print]

Cancer testis antigen SPAG9 is a promising marker for the diagnosis and treatment of lung cancer. Ren B1, Wei X1, Zou G2, et al. Oncol Rep. 2016 May;35(5):2599-605. doi: 10.3892/or.2016.4645. Epub 2016 Mar 1.

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. Mediavilla-Varela M1, Boateng K1, Noyes D1, Antonia SJ2,3. BMC Cancer. 2016 Mar 2;16(1):176. doi: 10.1186/s12885-016-2162-z.

Combined Use of Gene Expression Modeling and siRNA Screening Identifies Genes and Pathways Which Enhance the Activity of Cisplatin When Added at No Effect Levels to Non-Small Cell Lung Cancer Cells In Vitro. Leung AW1,2, Hung SS3, Backstrom I1, et al. PLoS One. 2016 Mar 3;11(3):e0150675. doi: 10.1371/journal.pone.0150675. eCollection 2016.

Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines. Bai XY1, Zhang XC1, Yang SQ1, An SJ1, Chen ZH1, Su J1, Xie Z1, Gou LY1,2, Wu YL1. PLoS One. 2016 Mar 4;11(3):e0149370. doi: 10.1371/journal.pone.0149370. eCollection 2016.

Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice. Kozlowska AK1,2, Kaur K1, Topchyan P1, Jewett A3,4. Cancer Immunol Immunother. 2016 Mar 31. [Epub ahead of print]

 

 

 

SCREENING, DIAGNOSIS AND STAGING

The potential of liquid biopsies. Buder A1, Tomuta C, Filipits M. Curr Opin Oncol. 2016 Mar;28(2): 130-4. doi: 10.1097/CCO.0000000000000267.

Computer Vision Tool and Technician as First Reader of Lung Cancer Screening CT Scans. Ritchie AJ1, Sanghera C2, Jacobs C3, et al. J Thorac Oncol. 2016 Mar 5. pii: S1556-0864(16)00360-9. doi: 10.1016/j.jtho.2016.01.021. [Epub ahead of print]

Diagnostic Accuracy and Safety of CT-Guided Percutaneous Transthoracic Needle Biopsies: 14-Gauge Versus 22-Gauge Needles. Ocak S1, Duplaquet F2, Jamart J3, et al. J Vasc Interv Radiol. 2016 Mar 23. pii: S1051-0443(16)00155-X. doi: 10.1016/j.jvir.2016.01.134. [Epub ahead of print]

Yield of Preoperative Whole-body CT in Patients Presenting with Single Brain Malignancy:: Experience at a Tertiary-care Center. Dong H1, Cox M2, Selvarajan S1, Roth C1, Deshmukh S1. Acad Radiol. 2016 Mar 29. pii: S1076-6332(16)00064-7. doi: 10.1016/j.acra.2015.12.024. [Epub ahead of print]

Standardized terminology and nomenclature for respiratory cytology: The Papanicolaou Society of Cytopathology guidelines. Layfield LJ1, Baloch Z2, Elsheikh T3, et al. Diagn Cytopathol. 2016 Mar 15. doi: 10.1002/dc.23457. [Epub ahead of print]

The Association between Smoking Abstinence and Mortality in the National Lung Screening Trial. Tanner NT1,2, Kanodra NM1, Gebregziabher M3,2, Payne E3, Halbert CH4,2, Warren GW5,6, Egede LE7,2, Silvestri GA1. Am J Respir Crit Care Med. 2016 Mar 1;193(5):534-41. doi: 10.1164/rccm.201507-1420OC.

Respiration-Averaged CT for Attenuation Correction of PET Images – Impact on PET Texture Features in Non-Small Cell Lung Cancer Patients. Cheng NM1,2, Fang YH3, Tsan DL4, Hsu CH2, Yen TC1. PLoS One. 2016 Mar 1;11(3):e0150509. doi: 10.1371/journal.pone.0150509. eCollection 2016.

A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer. Peng H1, Wang J1, Li J2, et al. Life Sci. 2016 Mar 2. pii: S0024-3205(16)30150-3. doi: 10.1016/j.lfs.2016.03.002. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – SURGERY

The Effect of Transcutaneous Electrıcal Nerve Stımulatıon on Post-Thoracotomy Paın. Erden S1, Senol Celik S2. Contemp Nurse. 2016 Mar 17:1-19. [Epub ahead of print]

Perioperative circulating tumor cells in surgical patients with non-small cell lung cancer: does surgical manipulation dislodge cancer cells thus allowing them to pass into the peripheral blood? Sawabata N1,2, Funaki S3, Hyakutake T4, Shintani Y3, Fujiwara A3, Okumura M3. Surg Today. 2016 Mar 7. [Epub ahead of print]

Robotic Versus Thoracoscopic Resection for Lung Cancer: Early Results of a New Robotic Program. Mungo B1, Hooker CM1, Ho JS1, Yang SC1, Battafarano RJ1, Brock MV1, Molena D2. J Laparoendosc Adv Surg Tech A. 2016 Mar 15. [Epub ahead of print]

Effect of Surgery on Quality of Life of Patients with Spinal Metastasis from Non-Small-Cell Lung Cancer. Tang Y1, Qu J2, Wu J3, Liu H1, Chu T1, Xiao J4, Zhou Y5. J Bone Joint Surg Am. 2016 Mar 2;98(5):396-402. doi: 10.2106/JBJS.O.00629.

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease. Bugge A1, Lund MB2, Brunborg C3, Solberg S4, Kongerud J5. Ann Thorac Surg. 2016 Mar 23. pii: S0003-4975(15)02099-8. doi: 10.1016/j.athoracsur.2015.12.057. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – CHEMOTHERAPY

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. Park K1, Yu CJ2, Kim SW3, et al. JAMA Oncol. 2016 Mar 1;2(3):305-12. doi: 10.1001/jamaoncol.2015.4921.

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. Solomon BJ1, Cappuzzo F2, Felip E2, et al. J Clin Oncol. 2016 Mar 28. pii: JCO635888. [Epub ahead of print]

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. Urata Y1, Katakami N2, Morita S2, et al. J Clin Oncol. 2016 Mar 28. pii: JCO634154. [Epub ahead of print]

Exploration of Imaging Biomarkers for Predicting Survival of Patients With Advanced Non-Small Cell Lung Cancer Treated With Antiangiogenic Chemotherapy. Hayano K1, Kulkarni NM1, Duda DG2, Heist RS3, Sahani DV1. AJR Am J Roentgenol. 2016 Mar 2:1-7. [Epub ahead of print]

A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients. Mo H1, Hao X1, Liu Y1, et al. Cancer Med. 2016 Mar 19. doi: 10.1002/cam4.689. [Epub ahead of print]

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Fehrenbacher L1, Spira A2, Ballinger M3, Kowanetz M3, et al. Lancet. 2016 Mar 9. pii: S0140-6736(16)00587-0. doi: 10.1016/S0140-6736(16)00587-0. [Epub ahead of print]

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. Li T1, LoRusso P2,3, Maitland ML4, Ou SH5, et al. J Hematol Oncol. 2016 Mar 10;9(1):23. doi: 10.1186/s13045-016-0254-5.

Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy. Park HS1, Lim SM, Shin HJ, et al. Pharmacogenet Genomics. 2016 Mar;26(3):116-25. doi: 10.1097/FPC.0000000000000196.

Phase II Study of a Non-platinum-containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab (PPB) as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Pietanza CM1, Hellmann MD1, Fiore JJ1, et al. J Thorac Oncol. 2016 Mar 7. pii: S1556-0864(16)00441-X. doi: 10.1016/j.jtho.2016.02.018. [Epub ahead of print]

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells. Dong X1, Fernandez-Salas E2, Li E3, Wang S4. Neoplasia. 2016 Mar;18(3):162-71. doi: 10.1016/j.neo.2016.02.001.

A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer. Kontopodis E1, Kotsakis A1, Kentepozidis N1, et al. Cancer Chemother Pharmacol. 2016 Mar 19. [Epub ahead of print]

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Kim DW1, Mehra R2, Tan DS3, et al. Lancet Oncol. 2016 Mar 10. pii: S1470-2045(15)00614-2. doi: 10.1016/S1470-2045(15)00614-2. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – RADIOTHERAPY

Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial. Movsas B1, Hu C2, Sloan J3, et al. JAMA Oncol. 2016 Mar 1;2(3):359-67. doi: 10.1001/jamaoncol.2015.3969.

Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer. Chiang CL1, Chen YW2, Wu MH3, Huang HC1, Tsai CM4, Chiu CH5. J Chin Med Assoc. 2016 Mar 29. pii: S1726-4901(16)00040-X. doi: 10.1016/j.jcma.2016.01.008. [Epub ahead of print]

Impact of the Radiation Dose on Survival after Radiochemotherapy for Small-cell Lung Cancer. Käsmann L1, Janssen S2, Schild SE3, Rades D4. Anticancer Res. 2016 Mar;36(3):1089-91.

Investigation of the 4D composite MR image distortion field associated with tumor motion for MR-guided radiotherapy. Stanescu T1, Jaffray D1. Med Phys. 2016 Mar;43(3):1550. doi: 10.1118/1.4941958.

A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II). Siva S1,2, Kron T3,4, Bressel M5, et al. BMC Cancer. 2016 Mar 4;16(1):183. doi: 10.1186/s12885-016-2227-z.

A new scheme for real-time high-contrast imaging in lung cancer radiotherapy: a proof-of-concept study. Yan H, Tian Z, Shao Y, Jiang SB, Jia X. Phys Med Biol. 2016 Mar 21;61(6):2372-88. doi: 10.1088/0031-9155/61/6/2372. Epub 2016 Mar 4.

Radiation Therapy Alone in cT1-3N0 Non-Small Cell Lung Cancer Patients Who are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules. Cho WK, Noh JM, Ahn YC, Oh D, Pyo H. Cancer Res Treat. 2016 Mar 9. doi: 10.4143/crt.2015.391. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – OTHER

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – SMALL CELL LUNG CANCER (SCLC)

A new hope: the immunotherapy in small cell lung cancer. Li Q, Yuan D, Ma C, Liu Y, Ma L, Lv T, Song Y. Neoplasma. 2016 Mar 14. doi: 10.4149/302_151001N511. [Epub ahead of print]

Benefit from thoracic radiotherapy in patients with extensive-disease small-cell lung cancer with elevated lactate dehydrogenase. Qin T1, Zhou N1, Zeng YD2, Dinglin X2, Zhao Y1, Liu H3, Chen L1. Onco Targets Ther. 2016 Mar 1;9:1095-103. doi: 10.2147/OTT.S97131. eCollection 2016.

New and emerging developments in extensive-stage small cell lung cancer therapeutics. Parikh M1, Riess J, Lara PN Jr. Curr Opin Oncol. 2016 Mar;28(2):97-103. doi: 10.1097/CCO.0000000000000264.

Evaluation of the role of remission status in a heterogeneous limited disease small-cell lung cancer patient cohort treated with definitive chemoradiotherapy. Manapov F1, Niyazi M2, Gerum S2, et al.. BMC Cancer. 2016 Mar 14;16(1):216. doi: 10.1186/s12885-016-2245-x.

MicroRNA-related polymorphisms in apoptosis pathway genes are predictive of clinical outcome in patients with limited disease small cell lung cancer. Jiang W1, Bi N1, Zhang WJ1, et al. Oncotarget. 2016 Mar 16. doi: 10.18632/oncotarget.8134. [Epub ahead of print]

PALLIATIVE AND SUPPORTIVE CARE

Development and Evaluation of Patient Education Materials for Elderly Lung Cancer Patients. Jewitt N1, Hope AJ1,2, Milne R1, et al. J Cancer Educ. 2016 Mar;31(1):70-4. doi: 10.1007/s13187-014-0780-1.

Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial. Deplanque G1, Gervais R2, Vergnenegre A3, et al. J Am Acad Dermatol. 2016 Mar 3. pii: S0190-9622(16)00068-2. doi: 10.1016/j.jaad.2016.01.019. [Epub ahead of print]

Inadequate Palliative Care in Chronic Lung Disease. An Issue of Health Care Inequality. Brown CE1, Jecker NS2, Curtis JR1. Ann Am Thorac Soc. 2016 Mar;13(3):311-6. doi: 10.1513/AnnalsATS.201510-666PS.

Opioid doses required for pain management in lung cancer patients with different cholesterol levels: negative correlation between opioid doses and cholesterol levels. Huang Z1, Liang L2, Li L3,4, et al. Lipids Health Dis. 2016 Mar 8;15(1):47. doi: 10.1186/s12944-016-0212-9.

 

COMPLEMENTARY & ALTERNATIVE THERAPY

Acupuncture and Related Therapies for Symptom Management in Palliative Cancer Care: Systematic Review and Meta-Analysis. Lau CH1, Wu X, Chung VC, et al. Medicine (Baltimore). 2016 Mar;95(9):e2901. doi: 10.1097/MD.0000000000002901.

Marsdenia tenacissima extract suppresses A549 cell migration through regulation of CCR5-CCL5 axis, Rho C, and phosphorylated FAK. Lin SS1, Li FF1, Sun L2, Fan W1, Gu M1, Zhang LY1, Qin S3, Yuan ST4.

Long-Term Effectiveness of Combined Treatment with Traditional Chinese Medicine and Western Medicine on the Prognosis of Patients with Lung Cancer. Tang WR1, Yang SH2,3, Yu CT4, et al. J Altern Complement Med. 2016 Mar;22(3):212-22. doi: 10.1089/acm.2015.0214.

Ling Zhi-8 reduces lung cancer mobility and metastasis through disruption of focal adhesion and induction of MDM2-mediated Slug degradation. Lin TY1, Hsu HY2. Cancer Lett. 2016 Mar 15. pii: S0304-3835(16)30166-5. doi: 10.1016/j.canlet.2016.03.018. [Epub ahead of print]

MISCELLANEOUS WORKS

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. Sacher AG1, Dahlberg SE2, Heng J3, Mach S3, Jänne PA4, Oxnard GR1. JAMA Oncol. 2016 Mar 1;2(3):313-20. doi: 10.1001/jamaoncol.2015.4482.

Value: Changes in the Detection and Recognition Thresholds of Three Basic Tastes in Lung Cancer Patients Receiving Cisplatin and Paclitaxel and Its Association with Nutritional and Quality of Life Parameters. Turcott JG1, Juárez-Hernández E1, De la Torre-Vallejo M1, Sánchez-Lara K1, Luvian-Morales J1, Arrieta O1,2. Nutr Cancer. 2016 Feb-Mar;68(2):241-9. doi: 10.1080/01635581.2016.1144075. Epub 2016 Mar 4.

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. Kazandjian D1, Suzman DL2, Blumenthal G2, et al. Oncologist. 2016 Mar 16. pii: theoncologist.2015-0507. [Epub ahead of print]

An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. Polite BN1,2, Cipriano-Steffens T3,4, Hlubocky F3,4, et al. J Racial Ethn Health Disparities. 2016 Mar 16. [Epub ahead of print]

HDAC inhibitors enhance T cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Zheng H1, Zhao W2, Yan C3, et al. Clin Cancer Res. 2016 Mar 10. pii: clincanres.2584.2015. [Epub ahead of print]

Patients’ Knowledge, Beliefs, and Distress associated with Detection and Evaluation of Incidental Pulmonary Nodules for Cancer: Results from a Multicenter Survey. Freiman MR1, Clark JA2, Slatore CG3, et al. J Thorac Oncol. 2016 Mar 1. pii: S1556-0864(16)00355-5. doi: 10.1016/j.jtho.2016.01.018. [Epub ahead of print]

Cancer Stage in American Indians and Alaska Natives Enrolled in Medicaid. Adams SV1, Burnett-Hartman AN2, Karnopp A3, et al. Am J Prev Med. 2016 Mar 24. pii: S0749-3797(16)00096-9. doi: 10.1016/j.amepre.2016.02.016. [Epub ahead of print]

 

 

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)